AbbVie's Mavyret for HCV gets FDA nod | FDA gives orphan status to Omeros' Berger's disease drug | "Right-to-try" measure clears Senate
ADVERTISEMENT
August 7, 2017
Bio SmartBrief
SIGN UP ⋅   FORWARD
Today's Top Story
AbbVie's Mavyret for HCV gets FDA nod
AbbVie's breakthrough therapy Mavyret, or glecaprevir and pibrentasvir, has been approved by the FDA as an eight-week regimen treatment for previously untreated patients with hepatitis C virus. The drug is indicated for adult patients with HCV genotypes 1 through 6 without cirrhosis or with mild cirrhosis, including those with moderate to severe renal disease and patients being treated with dialysis.
Seeking Alpha (free registration) (8/3) 
LinkedIn Twitter Facebook Google+ Email
Online Biotech Grad Programs from Johns Hopkins
Become a leader in biotechnology with a graduate program from Johns Hopkins AAP. We offer 8 flexible online graduate degrees and certificates ranging from Biotech to Regulatory Science. Gain the expertise necessary to excel in and beyond the lab at a world-renowned university. Learn more.
ADVERTISEMENT
Advertisement
Health Care & Policy
FDA gives orphan status to Omeros' Berger's disease drug
Omeros' breakthrough therapy OMS721, indicated to treat patients with the kidney disorder Berger's disease, has been granted orphan drug status by the FDA.
Seeking Alpha (free registration) (8/4) 
LinkedIn Twitter Facebook Google+ Email
"Right-to-try" measure clears Senate
The Senate unanimously approved legislation that would permit patients diagnosed with life-threatening illnesses who have exhausted other treatment options and cannot take part in clinical trials to use experimental treatments in the FDA approval pipeline as long as the drugs have undergone at least an early-stage clinical study. The right-to-try bill, sponsored by Sen. Ron Johnson, R-Wis., now moves to the House, where similar legislation is under consideration.
Medscape (free registration) (8/3),  Politico (8/3) 
LinkedIn Twitter Facebook Google+ Email
BLA for AndexXa refiled by Portola
Portola Pharmaceuticals has refiled its biologics license application for AndexXa, or andexanet alfa, with inclusion of additional manufacturing information per the FDA's request in a complete response letter issued a year ago. The drug is being developed for reversal of direct or indirect factor Xa inhibitors to address uncontrolled or life-threatening bleeding.
StreetInsider (8/3) 
LinkedIn Twitter Facebook Google+ Email
Perrigo's generic Mirvaso gets tentative FDA approval
The FDA has granted tentative approval to Perrigo's generic version of Galderma Laboratories' Mirvaso, or brimonidine topical gel, 0.33%. The drug is intended to treat adult patients with persistent erythema of rosacea.
Seeking Alpha (free registration) (8/4) 
LinkedIn Twitter Facebook Google+ Email
Legislation that would bolster pediatric cancer drugs receives Senate OK
The Senate has approved a bill that seeks to boost the pharmaceutical industry's spending on childhood cancer drug research and development, which is included in larger legislation that would reauthorize FDA user fees. The measure goes to President Donald Trump for his signature.
USA Today (8/3) 
LinkedIn Twitter Facebook Google+ Email
Over 35,800 industry leaders read SmartBrief
BIO SmartBrief helps marketers reach over 35,800 biotechnology industry leaders. Connect with your customers at all stages of the buying cycle! BIO SmartBrief is a smart way to drive qualified traffic, grow your brand and build actionable leads. Download your Media Kit.
ADVERTISEMENT
Company & Financial News
Bristol-Myers boosts cancer pipeline with IFM Therapeutics acquisition
Bristol-Myers Squibb said it will acquire IFM Therapeutics in an effort to strengthen its cancer portfolio. BMS will make a $300 million upfront payment, while IFM investors will also benefit from additional contingent payments that could reach $1.01 billion based on the achievement of specific milestones.
Reuters (8/3) 
LinkedIn Twitter Facebook Google+ Email
Celyad revises agreement with Celdara
Celyad revised its agreement with Celdara Medical to increase the share on future revenues from chimeric antigen receptor T NKR-2, being developed as treatment for refractory solid and hematological tumors, which showed "increased confidence in the clinical opportunity" during a Phase I study. Under the new terms of the deal, Celdara will receive an additional $12.5 million in cash and another $12.5 million in stock.
BioCentury (8/4) 
LinkedIn Twitter Facebook Google+ Email
The Latest From BIO ...
BIO has partnered with Illumina to offer exclusive rebates to first-time Illumina customers on the MiniSeq™ sequencer and other instruments that help you keep pace with technology and control your sequencing projects. Learn more!
LinkedIn Twitter Facebook Google+ Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
Food & Agriculture
Kenya OKs field trials of biotech corn, cotton
Kenya's National Biosafety Authority approved biotech corn and cotton field trials, which are scheduled to start in October. The assessment of the trials is "a step towards final application for release of the biotech maize into the market for either consumption or cultivation," Health Secretary Cleopa Mailu said.
Business Daily (Kenya) (8/2) 
LinkedIn Twitter Facebook Google+ Email
Hot Topics
Industrial & Environmental
Aemetis signs deal with InEnTec on cellulosic ethanol production
Aemetis signed an agreement with InEnTec to produce high-value, low-carbon cellulosic ethanol using InEnTec's advanced gasification technology until 2024. Aemetis will incorporate InEnTec's technology with LanzaTech's patented microbial fermentation technology.
Ethanol Producer Magazine online (8/4) 
LinkedIn Twitter Facebook Google+ Email
News From BIO
Become an advocate for biotechnology
Learn more about key policy issues affecting biotechnology in Washington, D.C., and state capitals around the country. With the unpredictability of the federal level coupled with the increasingly hostile state legislatures, it is vital that the biotechnology industry amplify its voice on the federal, state and local levels. Become an advocate for biotechnology by joining BIO Action today. Now, more than ever, we need your voice! Text BIO to 52886 or visit BIO's website.
LinkedIn Twitter Facebook Google+ Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
  
  
If you don't know where you're going, you might not get there.
Yogi Berra,
baseball player and manager
LinkedIn Twitter Facebook Google+ Email
  
  
The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Nicole Brown
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information